ADMA - Company ID 0001368514
ADMA BIOLOGICS, INC. trades as ADMA and has a market capitalization of $2.12 B, making it the #2088 largest US-listed company by market value. In its fiscal 2025 annual report the company posted revenue of $510.17M, up 19.6% from the prior year and net income of $146.93M. This page tracks ADMA BIOLOGICS, INC. through 984 SEC filings, with financial statements and metrics updated as new reports are filed.
Research snapshot
Updated
2026-07-09
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Next research step
Over the last 9 fiscal years ADMA BIOLOGICS, INC.'s revenue grew from $10.66M to $510.17M, a compound annual growth rate of 53.7%. Net profit margin expanded from -183.1% to 28.8% over the same period - every figure below comes from the company's audited annual filings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.
| Filing | Type | Filed |
|---|---|---|
| Insider trade | 4 | 2026-05-14 |
| Insider trade | 4 | 2026-05-12 |
| Quarterly report | 10-Q | 2026-05-06 |
| Major company event | 8-K | 2026-05-06 |
| Major company event | 8-K | 2026-05-04 |
| SCHEDULE 13G | - | 2026-04-29 |
| Annual report to shareholders | ARS | 2026-04-15 |
| Proxy materials | DEFA14A | 2026-04-15 |
ADMA Biologics Reports First Quarter 2026 Financial Results and Provides Business Update | ADMA Biologics, Inc.
ADMA Biologics Announces FDA Approval to Expand the Label for ASCENIV™ to Include Pediatric Immune Compromised Patients Two Years of Age and Older | ADMA Biologics, Inc.
To access the conference call seamlessly, participants are required to register for the call here to receive the dial-in numbers and unique PIN. It is recommended that you join approximately 10 minutes prior to the event start (although you may dial in at any time during the call). Attendees who will not be asking a question during the call are encouraged to listen in to the live webcast here . An archived replay of the event will be available located under “Events & Webcasts” in the investor section of the Company’s website at https://ir.admabiologics.com/events-webcasts .
ADMA Biologics Issues Statement Refuting Unsubstantiated, Misleading and Inaccurate Allegations by Culper Research | ADMA Biologics, Inc.
ADMA Biologics Addresses Misleading Short-Seller Report | ADMA Biologics, Inc.
The largest companies sharing ADMA BIOLOGICS, INC.'s SEC industry classification (biological products, (no diagnostic substances)).
ADMA BIOLOGICS, INC. (ADMA) has a market capitalization of $2.12 B as of 2026-07-09, ranking #2088 among US-listed companies.
ADMA BIOLOGICS, INC. reported revenue of $510.17M for fiscal year 2025, an increase of 19.6% year over year.
Yes. ADMA BIOLOGICS, INC. reported net income of $146.93M in its latest fiscal year.